This paradox in the findings of PHI-1 post-transcriptional regulation—where both its up- and downregulation contribute to cancer progression—suggests the presence of multiple PHI-1 targets within cancers and highlights the need for careful studies that consider the cancer type, genetic background, tumor microenvironment, and treatment conditions. The gene discussed is PPP1R14B; the disease is cancer.